EPREX(R) (epoetin alfa) Marketing Authorisation extended to include symptomatic anaemia
Janssen-Cilag announced the French health authority ANSM, has approved EPREX® (epoetin alfa) for treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes who have low serum erythropoietin (<200 mU/mL). March 24, 2017